Abstract
BACKGROUND AND OBJECTIVE The efficacy and safety of radiosensitivity on non-small cell lung cancer (NSCLC) using metronidazole amino acidum natrium (CMNa) are yet to be proven. This study evaluates the efficacy and safety of radiosensitivity on NSCLC by CMNa to provide references for further clinical practice and research. METHODS Relevant randomized controlled trials (RCTs) were obtained from the Cochrane library, Pubmed, EMbase, CBM, CNKI, VIP, and Wan Fang databases. Dates were searched through other means. RCTs of radiosensitivity on NSCLC by CMNa were included. The data included in the study were evaluated and analyzed using the Cochrane Collaboration's RevMan 5.1 software. RESULTS A total of 21 RCTs were included. The results of the meta-analyses showed that the total effective rate of the test group that received CMNa plus radiotherapy was higher than that of the control group that received radiotherapy alone (OR=3.29, 95%CI: 2.47-4.39, P<0.000,01) or radiotherapy plus placebo (OR=3.65, 95%CI: 2.25-5.92, P<0.000,01), respectively. No significant differences were found in the quality of life between one and two-year survival rates (P>0.05). No significant differences were found among radiation pneumonitis, radiation esophagitis, hematological toxicity, and cardiotoxicity (P>0.05). CONCLUSIONS CMNa plus radiotherapy elicit beneficial effects in the treatment of NSCLC and produce fewer adverse effects. Therefore, this technique can be recommended and applied in clinics.
